floxacillin Indications/Contra | FAERs-F | FAERs-M | Orange Bk | BioActivity |

Stem definitionDrug idCAS RN
antibiotics, 6-aminopenicillanic acid derivatives 1183 5250-39-5

Description:

MoleculeDescription

Molfile Inchi Smiles

Synonyms:

  • floxacillin
  • fluocloxacilin
  • flucloxacillin
  • fluoxacillin
  • flucloxacillin sodium
Antibiotic analog of CLOXACILLIN.
  • Molecular weight: 453.87
  • Formula: C19H17ClFN3O5S
  • CLOGP: 2.66
  • LIPINSKI: 0
  • HAC: 8
  • HDO: 2
  • TPSA: 112.74
  • ALOGS: -3.92
  • ROTB: 3

Drug dosage:

DoseUnitRoute
2 g O
2 g P

ADMET properties:

PropertyValueReference
MRTD (Maximum Recommended Therapeutic Daily Dose) 146.96 ┬ÁM/kg/day Contrera JF, Matthews EJ, Kruhlak NL, Benz RD
BDDCS (Biopharmaceutical Drug Disposition Classification System) 4 Hosey CM, Chan R, Benet LZ
BA (Bioavailability) 60 % Kim MT, Sedykh A, Chakravarti SK, Saiakhov RD, Zhu H
Vd (Volume of distribution) 0.19 L/kg Lombardo F, Berellini G, Obach RS
CL (Clearance) 2.40 mL/min/kg Lombardo F, Berellini G, Obach RS
fu (Fraction unbound in plasma) 0.04 % Lombardo F, Berellini G, Obach RS
t_half (Half-life) 1.40 hours Lombardo F, Berellini G, Obach RS

Approvals:

DateAgencyCompanyOrphan
Jan. 1, 1962 YEAR INTRODUCED

FDA Adverse Event Reporting System (Female)

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
Metabolic acidosis 281.98 23.22 122 5500 38658 46641782
Cellulitis 173.79 23.22 107 5515 70181 46610259
Drug interaction 149.77 23.22 151 5471 202943 46477497
Pyroglutamate increased 117.37 23.22 23 5599 406 46680034
Pyroglutamic acidosis 71.65 23.22 14 5608 243 46680197
Lip swelling 46.27 23.22 32 5590 25363 46655077
Perforation 43.51 23.22 12 5610 975 46679465
Neutropenic sepsis 41.56 23.22 23 5599 12301 46668139
Rash erythematous 39.74 23.22 33 5589 34317 46646123
Liver function test abnormal 38.56 23.22 37 5585 46450 46633990
Eczema herpeticum 37.57 23.22 7 5615 93 46680347
Superinfection 36.29 23.22 12 5610 1805 46678635
Clostridium difficile infection 35.19 23.22 27 5595 25076 46655364
Swollen tongue 33.64 23.22 28 5594 29204 46651236
Dermatitis allergic 33.12 23.22 20 5602 12583 46667857
Jaundice 31.89 23.22 27 5595 28818 46651622
Rash 31.28 23.22 104 5518 356408 46324032
Swelling face 30.99 23.22 35 5587 53024 46627416
Vulvovaginal inflammation 30.11 23.22 8 5614 564 46679876
Anterior interosseous syndrome 29.33 23.22 4 5618 4 46680436
Hypokalaemia 27.91 23.22 43 5579 87981 46592459
Blister 27.01 23.22 30 5592 44601 46635839
Full blood count abnormal 26.09 23.22 9 5613 1538 46678902
Angiodermatitis 25.01 23.22 5 5617 98 46680342
Drug-induced liver injury 24.52 23.22 22 5600 25346 46655094
Acute haemorrhagic oedema of infancy 24.47 23.22 4 5618 23 46680417
Strawberry tongue 23.91 23.22 4 5618 27 46680413
Acute kidney injury 23.55 23.22 72 5550 235783 46444657

FDA Adverse Event Reporting System (Male)

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
Drug interaction 165.12 20.62 180 4626 199388 29748284
Metabolic acidosis 103.38 20.62 68 4738 37393 29910279
Pyroglutamate increased 90.81 20.62 18 4788 249 29947423
Rhabdomyolysis 67.76 20.62 66 4740 63514 29884158
Acute kidney injury 59.08 20.62 133 4673 273709 29673963
Cellulitis 56.36 20.62 52 4754 46732 29900940
Drug level decreased 48.54 20.62 22 4784 5783 29941889
Genitalia external ambiguous 34.67 20.62 8 4798 234 29947438
Immunosuppressant drug level decreased 33.19 20.62 11 4795 1248 29946424
Drug reaction with eosinophilia and systemic symptoms 32.99 20.62 31 4775 28457 29919215
Congenital bladder anomaly 32.80 20.62 8 4798 298 29947374
Foetal hypokinesia 31.15 20.62 8 4798 369 29947303
Norovirus test positive 30.68 20.62 6 4800 77 29947595
Neonatal respiratory depression 30.05 20.62 8 4798 425 29947247
Pyroglutamic acidosis 29.27 20.62 6 4800 99 29947573
Chromaturia 28.40 20.62 21 4785 13844 29933828
Clostridium difficile infection 28.13 20.62 22 4784 15761 29931911
Osteomyelitis salmonella 27.94 20.62 5 4801 38 29947634
Inhibitory drug interaction 27.09 20.62 10 4796 1558 29946114
Heart transplant rejection 25.42 20.62 9 4797 1244 29946428
Lip swelling 23.22 20.62 18 4788 12726 29934946
Compartment syndrome 22.47 20.62 10 4796 2517 29945155
Stevens-Johnson syndrome 22.05 20.62 20 4786 17536 29930136
Skin exfoliation 20.87 20.62 22 4784 23150 29924522

Pharmacologic Action:

SourceCodeDescription
ATC J01CF05 ANTIINFECTIVES FOR SYSTEMIC USE
ANTIBACTERIALS FOR SYSTEMIC USE
BETA-LACTAM ANTIBACTERIALS, PENICILLINS
Beta-lactamase resistant penicillins
CHEBI has role CHEBI:36047 antibacterial drugs
MeSH PA D000900 Anti-Bacterial Agents
MeSH PA D000890 Anti-Infective Agents

Drug Use (View source of the data)

None

Acid dissociation constants calculated using MoKa v3.0.0

Dissociation levelDissociation constantType (acidic/basic)
pKa1 2.76 acidic

Orange Book patent data (new drug applications)

None

Orange Book exclusivity data (new drug applications)

None

Bioactivity Summary:

TargetClassPharosUniProtActionTypeActivity value
(-log[M])
Mechanism
action
Bioact sourceMoA source
Androgen receptor Nuclear hormone receptor IC50 6.25 WOMBAT-PK
Matrix metalloproteinase-9 Enzyme IC50 4.19 WOMBAT-PK
Penicillin-binding protein 1A Enzyme WOMBAT-PK

External reference:

IDSource
N0000167002 NUI
D01249 KEGG_DRUG
C0016267 UMLSCUI
CHEBI:5098 CHEBI
CHEMBL222645 ChEMBL_ID
DB00301 DRUGBANK_ID
D005436 MESH_DESCRIPTOR_UI
10910 IUPHAR_LIGAND_ID
2308 INN_ID
43B2M34G2V UNII
21319 PUBCHEM_CID
235750 RXNORM
003516 NDDF
003517 NDDF
387544009 SNOMEDCT_US
426208000 SNOMEDCT_US
96067005 SNOMEDCT_US

Pharmaceutical products:

None